Skip to main content

Table 2 Baseline laboratory investigations of type 2 diabetes mellitus patients divided according to the cardiovascular death

From: Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long‐term follow‐up study

Variable Non-survivors (n = 16) Survivors (n = 117) P-value
Basic
 HbA1c, % 6.7 (6.2–8.5) 6.4 (6.1–7.1) 0.25
 Fasting glucose, mmol/l 5.0 (4.2–6.5) 6.0 (5.3–7.4) 0.06
 Creatinine, µmol/l 82.0 (77.0–113.5) 81.0 (65.0–96.0) 0.17
 Total cholesterol, mmol/l 3.4 (3.3–4.4) 4.3 (3.6–5.0) 0.03
 LDL-cholesterol, mmol/l 1.7 (1.4–2.4) 2.4 (1.9–3.0) 0.01
 HDL-cholesterol, mmol/l 1.2 (1.0–1.5) 1.3 (1.1–1.6) 0.30
 Triglycerides, mmol/l 1.0 (0.9–1.6) 1.3 (1.0–1.8) 0.22
 High-sensitivity C-reactive protein, mg/l 3.3 (1.9–6.0) 1.9 (1.0–3.4) 0.04
Coagulation parameters
 Fibrinogen, g/l 3.2 (2.8–3.5) 3.0 (2.6–3.5) 0.32
 Peak thrombin, nM 253.5 (212.0–289.5) 228.0 (201.0–268.0) 0.17
 Plasminogen activity, % 105.5 (88.5–115.5) 105.0 (98.0–117.0) 0.48
 tPA antigen, ng/ml 11.8 (9.3–15.6) 11.2 (10.0–13.2) 0.49
 PAI-1 antigen, ng/ml 32.1 (29.5–37.1) 32.1 (29.5–37.1) 0.88
 α2-antiplasmin activity, % 115.0 (101.0–121.0) 115.0 (101.0–121.0) 0.16
 TAFI activity, % 97.5 (89.0–106.0) 97.5 (89.0–106.0) 0.72
 Thrombomodulin antigen, ng/ml 3.1 (2.3–3.6) 3.01 (2.3–3.6) 0.91
Fibrin clot properties
 Lag phase, s 42.5 (40.0–44.5) 43.0 (40.0–46.0) 0.67
 ∆Abs, 405 nm 0.825 (0.800–0.860) 0.810 (0.770–0.850) 0.26
 Ks, × 10–9 cm2 7.0 (6.2–7.3) 7.1 (6.6–7.7) 0.13
 Compaction, % 44.0 (39.5–46.0) 44.0 (40.0–49.0) 0.47
 CLT, min 88.0 (79.0–104.5) 95.0 (82.0–105.0) 0.45
 t50%, min 10.15 (9.60–10.95) 9.8 (9.0–10.4) 0.06
 D-Dmax, mg/l 4.18 (3.77–4.48) 3.85 (3.60–4.09) 0.01
 D-Drate, mg/l/min 0.069 (0.064–0.071) 0.070 (0.068–0.073) 0.02
  1. Data are presented as the median (interquartile range) and compared using Mann–Whitney test
  2. HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, tPA tissue plasminogen activator, PAI plasminogen activator inhibitor 1, TAFI thrombin-activatable fibrinolysis inhibitor, Ks permeability coefficient, ∆Abs maximum absorbance at plateau, t50% the time required for a 50% decrease in clot turbidity, CLT clot lysis time, D-Dmax maximum D-dimer concentrations, D-Drate maximum rates of increase in D-dimer levels